Scanfil Oyj
SCANFIL PLC MANAGERS' TRANSACTIONS 2 March 2021 10.30 A.M.
Scanfil Plc - Managers' Transactions
____________________________________________
Person subject to the notification requirement
Name: Kristoffer Asklöv
Position: Other senior manager
Issuer: Scanfil Oyj
LEI: 7437004XD6U0FFDCT507
Notification type: INITIAL NOTIFICATION
Reference number: 7437004XD6U0FFDCT507_20210301185930_2
____________________________________________
Transaction date: 2021-03-01
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI4000029905
Nature of the transaction: DISPOSAL
Transaction details
(1): Volume: 861 Unit price: 7.42 EUR
(2): Volume: 129 Unit price: 7.42 EUR
(3): Volume: 1 Unit price: 7.42 EUR
(4): Volume: 560 Unit price: 7.4 EUR
(5): Volume: 581 Unit price: 7.4 EUR
(6): Volume: 635 Unit price: 7.4 EUR
(7): Volume: 13 Unit price: 7.4 EUR
(8): Volume: 5,220 Unit price: 7.4 EUR
Aggregated transactions
(8): Volume: 8,000 Volume weighted average price: 7.40248 EUR
SCANFIL PLC
Petteri Jokitalo
CEO
For additional information:
CEO Petteri Jokitalo
tel. +358 8 4882 111
www.scanfil.com
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ROCKWOOL A/S5.11.2025 13:04:11 CET | Press release
ROCKWOOL A/S – transactions in connection with share buy-back programme
Rockwool A/S5.11.2025 13:04:11 CET | Pressemeddelelse
ROCKWOOL A/S – transaktioner i henhold til aktietilbagekøbsprogram
Centessa Pharmaceuticals plc5.11.2025 13:00:00 CET | Press release
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program
MoonLake Immunotherapeutics AG5.11.2025 13:00:00 CET | Press release
MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab
Teva Pharmaceutical Industries Ltd5.11.2025 13:00:00 CET | Press release
Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
